Tenon Medical (TNON)

Executive Summary

Tenon Medical is a medical device company focused on revolutionizing sacroiliac (SI) joint fusion with its Catamaran SI Joint Fusion System. The system utilizes a single, robust titanium implant delivered via a proprietary inferior-posterior surgical approach, offering a minimally invasive alternative to traditional SI joint fusion procedures. SI joint dysfunction affects a significant portion of the chronic low back pain population, representing a substantial market opportunity. The company is headquartered in Campbell, California and is publicly traded under the ticker TNON. Tenon Medical has been gaining traction in the orthopedic device space, driven by positive clinical outcomes and expanding surgeon adoption. The company's strategic focus remains on commercial execution, clinical evidence generation, and broadening its product portfolio. With a lean cost structure and a clear regulatory pathway, Tenon is positioned to capture share in the growing SI joint fusion market. However, the company faces competitive pressure from larger orthopedic players and must demonstrate sustained sales growth to achieve profitability.

Upcoming Catalysts (preview)

• Q1 2026Q4 2025 revenue report exceeding analyst expectations40% success
• Q2 2026Publication of long-term clinical data for Catamaran system60% success
• Q3 2026FDA 510(k) clearance for expanded indications or next-gen implant50% success